These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16130177)

  • 1. Development of HIV fusion inhibitors.
    Schneider SE; Bray BL; Mader CJ; Friedrich PE; Anderson MW; Taylor TS; Boshernitzan N; Niemi TE; Fulcher BC; Whight SR; White JM; Greene RJ; Stoltenberg LE; Lichty M
    J Pept Sci; 2005 Nov; 11(11):744-53. PubMed ID: 16130177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 3. Enfuvirtide.
    Lalezari JP; Luber AD
    Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
    Jamjian MC; McNicholl IR
    Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 6. Enfuvirtide (T-20): potentials and challenges.
    Foy K; Juethner SN
    J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfuvirtide, the first fusion inhibitor to treat HIV infection.
    Poveda E; Briz V; Soriano V
    AIDS Rev; 2005; 7(3):139-47. PubMed ID: 16302461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
    Cooper DA; Lange JM
    Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfuvirtide: from basic investigations to current clinical use.
    Joly V; Jidar K; Tatay M; Yeni P
    Expert Opin Pharmacother; 2010 Nov; 11(16):2701-13. PubMed ID: 20977403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
    Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD;
    J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
    Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
    Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
    AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.